Board reshuffle at Rite Aid after 2 failed merger attempts |

Board reshuffle at Rite Aid after 2 failed merger attempts

The Associated Press
In this Feb. 10, 2017, file photo, a man walks by a Rite Aid pharmacy in the Oakland section of Pittsburgh. After two failed buyouts, Rite Aid will shuffle its board of directors and spread out leadership at the top of the drugstore chain. Rite Aid said Thursday, Sept. 27, 2018, that three new, independent directors will be nominated to its board, and CEO John Standley will no longer hold the title of chairman. That will go to current board member Bruce Bodaken. (AP Photo/Gene J. Puskar, File)

After two failed buyout attempts that could have put it in a better position to compete against larger rivals, Rite Aid is shuffling its board of directors and dividing power at the top of the drugstore chain.

Rite Aid said Thursday that three new, independent directors will be nominated to its board and that CEO John Standley will no longer hold the title of chairman. That goes to current board member Bruce Bodaken.

Shareholders will vote next month on whether to approve new board nominees Robert Knowling Jr., Louis Miramontes and Arun Nayar. They would replace current directors David Jessick, Myrtle Potter and Frank Savage.

The company accelerated a board shake-up after speaking with shareholders in the wake of a failed buyout attempt by the grocer Albertsons, Bodaken said in a prepared statement.

The collapse of the Albertson’s deal followed another proposed buyout, from Walgreens, which ended the same way. Walgreens eventually agreed to buy nearly 2,000 stores from Rite Aid Corp.

Rite Aid, after the sale of its stores, has about 2,500 locations located mostly on the East and West coasts, as well as a pharmacy benefit management business that runs prescription drug coverage.

It planned to sell those assets in a separate deal with Albertsons, but called off that agreement before a shareholder vote last month. It had already received bad reviews from two prominent shareholder advisory firms and one of the drugstore chain’s biggest stock owners, Highfields Capital Management.

A couple days before it quashed the sale, the Camp Hill, Pennsylvania, company slashed its annual earnings forecast.

Rite Aid is trying to hold off bigger, national rivals like Walgreens or CVS Health Corp. partially by shoring up its share of business in regions where it already has a big presence. But it’s not getting any easier.

CVS is spending around $69 billion to acquire the health insurer Aetna Inc., and another insurer, Cigna Corp., is spending roughly $52 billion to acquire pharmacy benefit manger Express Scripts Holding Co. in a separate deal.

Rite Aid also reported on Thursday fiscal second-quarter earnings that narrowly missed the consensus expectation on Wall Street.

Shares of Rite Aid have plunged more than 30 percent so far this year, but the stock price climbed 2 percent, or three cents, to $1.31 in morning trading while broader indexes also rose.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.